Chinese pharmaceutical firms Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196; HKG: 2196) and Hangzhou Jiuyuan Gene Engineering Co., Ltd. (HKG: 2566) have entered into a strategic partnership to commercialize multiple biologic drugs and innovative drug-device combination products globally. This collaboration aims to leverage Fosun Pharma’s extensive commercialization network to accelerate market entry for Jiuyuan Gene’s products.
Collaboration Details
Under the agreement, Fosun Pharma secures exclusive rights for the clinical development, regulatory filing, manufacturing, and commercialization of Jiuyuan Gene’s products, including semaglutide, the rhBMP-2-containing bone repair material, and JY-23. These rights extend to the Middle East & North Africa (MENA) region, all Sub-Saharan African countries, and select ASEAN nations.
Market Presence and Partnerships
Fosun Pharma has established a robust commercialization network in these target markets. In Africa, its sales network covers over 40 countries and regions, with strong distribution capabilities in both English-speaking and French-speaking Sub-Saharan Africa. In the Middle East, Fosun Pharma formed a strategic collaboration with Saudi Arabia’s leading healthcare provider, Fakeeh Care Group, in April 2025. Additionally, in November 2024, Fosun Pharma partnered with SVAX to establish a joint venture in Saudi Arabia, aiming to enhance access to innovative and high-value products across the Middle East, North Africa, and Turkey (MENAT).-Fineline Info & Tech
